Related Articles
Atezolizumab/Cabozantinib vs Docetaxel in Previously Treated Metastatic NSCLC
The phase III CONTACT-01 trial evaluated atezolizumab plus cabozantinib vs docetaxel in patients with metastatic NSCLC after they had received checkpoint inhibitor treatment and chemotherapy.
New Findings Suggest No Correlation Between GLP-1 Receptor Agonists and Thyroid Cancer Risk
A recent study examined whether glucagon-like peptide (GLP)-1 receptor agonists are associated with an increased risk of thyroid cancer.
Cabozantinib in Advanced Adrenocortical Carcinoma
In a single-center phase II trial, cabozantinib monotherapy showed activity in adult patients with advanced adrenocortical carcinoma.
Study Identifies Genetic Variants Potentially Linked to Prevalent or Persistent HPV Infections
Investigators have uncovered new genetic variants that may predispose certain female patients to prevalent or persistent HPV infections and increase their risk of developing cervical…
Cabozantinib in Advanced Adrenocortical Carcinoma
In a single-center phase II trial, cabozantinib monotherapy showed activity in adult patients with advanced adrenocortical carcinoma.
ALK-Positive NSCLC: Adjuvant Alectinib vs Platinum-Based Chemotherapy
The phase III ALINA trial has shown significantly improved disease-free survival with adjuvant alectinib vs platinum-based chemotherapy in patients with resected ALK-positive NSCLC.
Progression-Free Survival Benefit Confirmed With Triplet Combination in BRCA Wild-Type, HRD-Positive Ovarian Cancer
The combination of immunotherapy, targeted therapy, and chemotherapy could be the new standard first-line treatment of patients with high-grade, advanced ovarian cancer with BRCA wild-type,…
Breast Cancer With Sentinel Node Metastases: Axillary Dissection vs Sentinel Node Biopsy Alone
The phase III SENOMAC trial showed noninferiority in recurrence-free survival with sentinel node biopsy alone vs completion axillary node dissection in patients with breast cancer…
Newly Diagnosed Locally Advanced HNSCC: Adding Pembrolizumab to Concurrent Chemoradiotherapy
The phase III KEYNOTE-412 trial showed no significant improvement in event-free survival with the addition of pembrolizumab to concurrent chemoradiotherapy in newly diagnosed patients with…
Illuminating a Potential Culprit in Melanoma Treatment Resistance
Researchers may have uncovered the mechanisms behind the development of targeted therapy resistance in melanoma.